Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Insider Sells 29,325 Shares of Stock

Key Points

• Insider John F. Paolini sold 29,325 shares of Kiniksa Pharmaceuticals at an average price of $32.55, resulting in a total transaction value of $954,528.75, which decreased his ownership in the company by 33.81%.
• Kiniksa Pharmaceuticals reported earnings of $0.23 per share for the last quarter, surpassing analyst expectations of $0.18. The company also achieved $156.80 million in revenue, exceeding forecasts.
• Research analysts maintain a favorable outlook on Kiniksa Pharmaceuticals, with multiple firms setting target prices between $36.00 and $54.00, while the average target price stands at $41.17.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) insider John F. Paolini sold 29,325 shares of the business's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $32.55, for a total transaction of $954,528.75. Following the completion of the transaction, the insider owned 57,403 shares in the company, valued at $1,868,467.65. The trade was a 33.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA traded up $0.59 during trading hours on Wednesday, reaching $33.37. The stock had a trading volume of 92,819 shares, compared to its average volume of 694,067. Kiniksa Pharmaceuticals International, plc has a 1 year low of $17.82 and a 1 year high of $33.98. The firm's 50 day moving average is $29.12 and its 200-day moving average is $24.77. The stock has a market capitalization of $2.47 billion, a price-to-earnings ratio of 834.18 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. Analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current year.

Institutional Trading of Kiniksa Pharmaceuticals International

A number of large investors have recently bought and sold shares of the business. Quadrature Capital Ltd acquired a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth $289,000. AXQ Capital LP acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $289,000. Franklin Resources Inc. lifted its stake in shares of Kiniksa Pharmaceuticals International by 62.2% in the 2nd quarter. Franklin Resources Inc. now owns 108,574 shares of the company's stock worth $3,004,000 after acquiring an additional 41,632 shares during the period. Hillsdale Investment Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $5,550,000. Finally, Catalyst Funds Management Pty Ltd acquired a new stake in shares of Kiniksa Pharmaceuticals International in the 2nd quarter worth $493,000. Institutional investors and hedge funds own 53.95% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on KNSA. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 2nd. Jefferies Financial Group upped their price objective on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a report on Tuesday, July 29th. Wedbush reiterated an "outperform" rating and set a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Monday, July 21st. Finally, Wells Fargo & Company increased their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $41.17.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.